vs
Cue Biopharma, Inc.（CUE）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是Cue Biopharma, Inc.的1.2倍（$27.1M vs $21.9M），Cue Biopharma, Inc.净利率更高（7.2% vs -120.8%，领先128.0%），Cue Biopharma, Inc.同比增速更快（1292.3% vs -10.5%），过去两年Cue Biopharma, Inc.的营收复合增速更高（257.5% vs 15.2%）
Cue Biopharma是一家临床阶段生物技术企业，专注于开发针对癌症、自身免疫性疾病和炎症疾病的新型靶向免疫疗法，其专有平台可精准调节T细胞活性，主要业务覆盖北美地区，与全球药企合作推进核心候选产品的临床试验。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
CUE vs RUM — 直观对比
营收规模更大
RUM
是对方的1.2倍
$21.9M
营收增速更快
CUE
高出1302.7%
-10.5%
净利率更高
CUE
高出128.0%
-120.8%
两年增速更快
CUE
近两年复合增速
15.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $21.9M | $27.1M |
| 净利润 | $1.6M | $-32.7M |
| 毛利率 | — | 5.5% |
| 营业利润率 | 9.0% | -131.1% |
| 净利率 | 7.2% | -120.8% |
| 营收同比 | 1292.3% | -10.5% |
| 净利润同比 | 116.7% | 86.2% |
| 每股收益（稀释后） | $0.05 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CUERUM
| Q4 25 | $21.9M | $27.1M | ||
| Q3 25 | $2.1M | $24.8M | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $421.0K | $23.7M | ||
| Q4 24 | $1.6M | $30.2M | ||
| Q3 24 | $3.3M | $25.1M | ||
| Q2 24 | $2.7M | $22.5M | ||
| Q1 24 | $1.7M | $17.7M |
净利润CUERUM
| Q4 25 | $1.6M | $-32.7M | ||
| Q3 25 | $-7.4M | $-16.3M | ||
| Q2 25 | $-8.5M | — | ||
| Q1 25 | $-12.3M | $-2.7M | ||
| Q4 24 | — | $-236.8M | ||
| Q3 24 | $-8.7M | $-31.5M | ||
| Q2 24 | $-10.2M | $-26.8M | ||
| Q1 24 | $-12.3M | $-43.3M |
毛利率CUERUM
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
营业利润率CUERUM
| Q4 25 | 9.0% | -131.1% | ||
| Q3 25 | -353.4% | -113.6% | ||
| Q2 25 | -292.3% | — | ||
| Q1 25 | -2921.4% | -153.5% | ||
| Q4 24 | — | -80.1% | ||
| Q3 24 | -264.2% | -131.0% | ||
| Q2 24 | -390.6% | -172.7% | ||
| Q1 24 | -737.8% | -197.4% |
净利率CUERUM
| Q4 25 | 7.2% | -120.8% | ||
| Q3 25 | -346.6% | -65.7% | ||
| Q2 25 | -287.1% | — | ||
| Q1 25 | -2911.4% | -11.2% | ||
| Q4 24 | — | -783.2% | ||
| Q3 24 | -259.6% | -125.9% | ||
| Q2 24 | -382.7% | -119.2% | ||
| Q1 24 | -719.1% | -244.1% |
每股收益（稀释后）CUERUM
| Q4 25 | $0.05 | $-0.13 | ||
| Q3 25 | $-0.07 | $-0.06 | ||
| Q2 25 | $-0.09 | — | ||
| Q1 25 | $-0.17 | $-0.01 | ||
| Q4 24 | — | $-1.17 | ||
| Q3 24 | $-0.17 | $-0.15 | ||
| Q2 24 | $-0.20 | $-0.13 | ||
| Q1 24 | $-0.25 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $27.1M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $26.4M | $274.8M |
| 总资产 | $42.2M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CUERUM
| Q4 25 | $27.1M | $237.9M | ||
| Q3 25 | $11.7M | $269.8M | ||
| Q2 25 | $27.5M | — | ||
| Q1 25 | $13.1M | $301.3M | ||
| Q4 24 | $22.5M | $114.0M | ||
| Q3 24 | $32.4M | $132.0M | ||
| Q2 24 | $30.0M | $154.2M | ||
| Q1 24 | $41.0M | $183.8M |
总债务CUERUM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.0M | — | ||
| Q2 24 | $2.0M | — | ||
| Q1 24 | $3.0M | — |
股东权益CUERUM
| Q4 25 | $26.4M | $274.8M | ||
| Q3 25 | $13.2M | $302.2M | ||
| Q2 25 | $18.2M | — | ||
| Q1 25 | $6.6M | $339.6M | ||
| Q4 24 | $17.5M | $-63.1M | ||
| Q3 24 | $25.4M | $166.1M | ||
| Q2 24 | $21.6M | $192.7M | ||
| Q1 24 | $30.0M | $210.7M |
总资产CUERUM
| Q4 25 | $42.2M | $336.8M | ||
| Q3 25 | $31.6M | $367.2M | ||
| Q2 25 | $40.7M | — | ||
| Q1 25 | $22.3M | $391.1M | ||
| Q4 24 | $32.2M | $195.3M | ||
| Q3 24 | $44.8M | $217.2M | ||
| Q2 24 | $42.3M | $243.2M | ||
| Q1 24 | $54.0M | $263.0M |
负债/权益比CUERUM
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.09× | — | ||
| Q1 24 | 0.10× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.1M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-31.7M |
| 自由现金流率自由现金流/营收 | — | -117.2% |
| 资本支出强度资本支出/营收 | 0.0% | 8.5% |
| 现金转化率经营现金流/净利润 | -0.68× | — |
| 过去12个月自由现金流最近4个季度 | — | $-70.8M |
8季度趋势，按日历期对齐
经营现金流CUERUM
| Q4 25 | $-1.1M | $-29.4M | ||
| Q3 25 | $-9.0M | $-10.6M | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.2M | $-14.5M | ||
| Q4 24 | $-36.3M | $-12.4M | ||
| Q3 24 | $-7.5M | $-19.1M | ||
| Q2 24 | $-10.0M | $-21.7M | ||
| Q1 24 | $-9.8M | $-33.9M |
自由现金流CUERUM
| Q4 25 | — | $-31.7M | ||
| Q3 25 | — | $-12.0M | ||
| Q2 25 | $-3.4M | — | ||
| Q1 25 | $-8.3M | $-14.6M | ||
| Q4 24 | $-36.4M | $-12.4M | ||
| Q3 24 | $-7.5M | $-19.9M | ||
| Q2 24 | $-10.0M | $-23.1M | ||
| Q1 24 | $-9.8M | $-34.3M |
自由现金流率CUERUM
| Q4 25 | — | -117.2% | ||
| Q3 25 | — | -48.6% | ||
| Q2 25 | -116.5% | — | ||
| Q1 25 | -1976.7% | -61.7% | ||
| Q4 24 | -2309.3% | -40.9% | ||
| Q3 24 | -225.7% | -79.5% | ||
| Q2 24 | -376.2% | -102.8% | ||
| Q1 24 | -573.0% | -193.3% |
资本支出强度CUERUM
| Q4 25 | 0.0% | 8.5% | ||
| Q3 25 | 0.0% | 5.7% | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 35.6% | 0.6% | ||
| Q4 24 | 4.2% | 0.1% | ||
| Q3 24 | 0.0% | 3.4% | ||
| Q2 24 | 0.4% | 6.1% | ||
| Q1 24 | 3.2% | 2.4% |
现金转化率CUERUM
| Q4 25 | -0.68× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CUE
| Immuno Scape Collaboration And License Agreement | $9.5M | 43% |
| BI Collaboration And License Agreement | $8.1M | 37% |
| Other | $4.3M | 20% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
